Results

Generally, RABBIT shows biologic DMARDs to be effective, safe and well tolerated in daily rheumatologic care. Used by experienced rheumatologists, they are a safe treatment option for patients with rheumatoid arthritis, who do not respond adequately to non-biologic DMARDs.

In practice, biologic DMARDs are not prescribed until non-biologic DMARDs fail or are not tolerated. That means that patients for whom biologic DMARDs are indicated differ systematically from patients who are treated with non-biologic DMARDs. Therefore, highly sophisticated statistical methods are required to compare patients on biologic and non-biologic DMARDs. Here, we will give a short insight into our published results.

Enrolment

Eingeschlossene Patienten: 19.247 (Stand 04. Februar 2020) 
Amgevita® (Adalimumab)65
Benepali® (Etanercept)653
Cimzia® (Certolizumab)908
Enbrel® (Etanercept)2860
Erelzi® (Etanercept)234
Flixabi® (Infliximab)3
Hulio® (Adalimumab)19
Humira® (Adalimumab)2905
Hyrimoz® (Adalimumab)48
Idacio® (Adalimumab)2
Imraldi® (Adalimumab)68
Inflectra™ (Infliximab)16
Kevzara® (Sarilumab)117
Kineret® (Anakinra)89
MabThera® (Rituximab)1459
Olumiant® (Baricitinib)355
Orencia® (Abatacept)807
Remicade® (Infliximab)762
Remsima® (Infliximab)11
Rixathon® (Rituximab)9
RoActemra® (Tocilizumab)1326
Simponi® (Golimumab)444
Xeljanz® (Tofacitinib)277
Zessly® (Infliximab)2
Kontrollen5808

Update: August 1st, 2018; enrolled patients: 17,522

Benepali® (Etanercept)   447
Cimzia® (Certolizumab)   841
Enbrel® (Etanercept) 2859
Erelzi® (Etanercept)     65
Flixabi® (Infliximab)       1
Humira® (Adalimumab) 2883
Inflectra® (Infliximab)     16
Kevzara® (Sarilumab)     20
Kineret® (Anakinra)     89
MabThera® (Rituximab)  1459
Olumiant® (Baricitinib)    167
Orencia® (Abatacept)    718
Remicade® (Infliximab)    762
Remsima® (Infliximab)       9
RoActemra® (Tocilizumab)  1260
Simponi® (Golimumab)    428
Xeljanz® (Tofacitinib)    106
Control Group  5392